Clinical Trials
3
Active:0
Completed:3
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Study
Completed
- Conditions
- Meningococcal MeningitisMeningococcal Infections
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2016-04-12
- Lead Sponsor
- JN-International Medical Corporation
- Target Recruit Count
- 50
- Registration Number
- NCT02500511
- Locations
- 🇺🇸
IRC Clinics, Towson, Maryland, United States
Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Phase 2
Completed
- Conditions
- Meningococcal MeningitisMeningococcal Infections
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2015-04-23
- Lead Sponsor
- JN-International Medical Corporation
- Target Recruit Count
- 525
- Registration Number
- NCT01897402
- Locations
- 🇺🇸
Mid Atlantic Urology Associates LLC, Greenbelt, Maryland, United States
🇺🇸Chesapeake Research Group, Pasadena, Maryland, United States
🇺🇸IRC Clinics, Towson, Maryland, United States
Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis
Phase 1
Completed
- Conditions
- Meningococcal InfectionsMeningococcal Meningitis
- First Posted Date
- 2011-11-30
- Last Posted Date
- 2013-01-14
- Lead Sponsor
- JN-International Medical Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT01482052
- Locations
- 🇺🇸
Kings Cardiology Group, Hanford, California, United States
News
No news found